Thank you for Subscribing to Life Science Review Weekly Brief
Russ Addis joins NeuExcell Therapeutics as Vice President, Research.
FREMONT, CA: NeuExcell Therapeutics Inc. is happy to announce the immediate hiring of Russ Addis, PhD, to the newly created position of Vice President, Research.
Dr Addis will report directly to Chief Executive Officer Dr Ronald HW Lorijn and be responsible for the company's gene therapy projects. Dr Addis oversees a developing group and will expand on previous initiatives and the lab's ongoing expansion.
Dr Addis joins NeuExcell with over eight years of industry experience at numerous startup biotech businesses and several years of research at the University of Pennsylvania's Institute for Regenerative Medicine. Before joining NeuExcell, Dr Addis founded and directed Aro Biotherapeutics' research program, which focused on developing targeted genetic treatments for rare diseases. Addis is uniquely qualified to head NeuExcell's research activities due to his expertise in various therapeutic areas, including gene therapy, neurodegeneration, rare illness, ageing, and oncology.
Dr Addis earned his undergraduate degree from the University of Pennsylvania with a double major in Biochemistry and Biology and his doctorate from the Johns Hopkins University School of Medicine in Human Genetics and Molecular Biology.
Dr Lorijn states that NeuExcell is thrilled to have Russ take on this new job in a press conference. This addition to the team shows NeuExcell's growing emphasis on internal innovation to secure the company's long-term success and benefit all those affected by severe neurodegenerative diseases.
NeuExcell co-founder and Chief Scientific Advisor, Professor Gong Chen adds that Russ possesses an unmatched combination of in-depth expertise and experience in neurology, gene therapy, and regenerative medicine. NeuExcell is optimistic that Russ will accelerate our research programs' translation to the clinic.